G1 Therapeutics. has filed a patent for a combination therapy involving a selective, fast-acting, short half-life CDK 4/6 inhibitor, chemotherapy, and a checkpoint inhibitor. The patent claims that the specific dosage regimen of the CDK 4/6 inhibitor during chemotherapy administration has a significant impact on immune cells in the cancer microenvironment, leading to improved tumor/cancer treatment outcomes. GlobalData’s report on G1 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights G1 Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on G1 Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. G1 Therapeutics's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

A patent filed for a combination therapy for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: G1 Therapeutics Inc

A recently filed patent (Publication Number: US20230302001A1) describes a method for treating cancer in humans. The method involves administering a therapeutic regimen consisting of an induction phase and a maintenance phase. In the induction phase, a selective Cyclin Dependent Kinase 4/6 (CDK4/6) inhibitor is administered to the patient. The patent claims that this CDK4/6 inhibitor can have a specific chemical structure.

The patent also claims that the therapeutic regimen includes the administration of an immune checkpoint inhibitor during both the induction and maintenance phases. The immune checkpoint inhibitor can be selected from a group that includes Programmed Cell Death-1 (PD-1) inhibitors, Programmed Cell Death-Ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors. Specific examples of PD-L1 inhibitors mentioned in the patent are atezolizumab, avelumab, and durvalumab. Examples of PD-1 inhibitors mentioned are nivolumab, pidilizumab, and pembrolizumab. Examples of CTLA-4 inhibitors mentioned are ipilimumab and tremelimumab.

The patent further claims that the therapeutic regimen includes the administration of a chemotherapeutic agent during the induction phase. The chemotherapeutic agent can be selected from a group that includes various types of drugs such as protein synthesis inhibitors, DNA-damaging chemotherapeutics, alkylating agents, topoisomerase inhibitors, and many others. Specific examples of chemotherapeutic agents mentioned in the patent are carboplatin, cisplatin, oxaliplatin, 5-fluorouracil, gemcitabine, and paclitaxel, among others.

The patent also specifies that the immune checkpoint inhibitor is administered every three weeks during both the induction and maintenance phases. Additionally, the patent claims that the method can be used to treat various types of cancer, including small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, bladder cancer, gastroesophageal cancer, cholangiocarcinoma, cervical cancer, and soft tissue sarcoma.

In summary, the filed patent describes a method for treating cancer in humans using a therapeutic regimen that includes a CDK4/6 inhibitor, an immune checkpoint inhibitor, and a chemotherapeutic agent. The method can be used to treat various types of cancer and involves specific administration schedules and dosages for the different components of the regimen.

To know more about GlobalData’s detailed insights on G1 Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies